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Abstract It has been reported that prostate apoptosis response-
4 (PAR-4) binds to and inhibits protein kinase Cj (PKCj) which
phosphorylates IUB kinase L (IKKL) for nuclear factor UB
(NFUB) activation, while p62 binds to and recruits PKCj to the
NFUB signaling complex. Thus, a mechanism to coordinate the
two binding proteins for the regulation of PKCj is expected to
exist. The present data show that p62 and PAR-4 do not compete
for PKCj binding but directly interact each other and form a
ternary complex with PKCj. Furthermore, p62 not only
enhances the catalytic activity of PKCj but also reactivates
catalytically inactive PAR-4-bound PKCj. As the result, over-
expression of p62 protects cells from PAR-4-mediated inactiva-
tion of NFUB and apoptotic death. Thus, the regulatory role of
p62 for free and PAR-4-bound PKCj is important in activation
of NFUB. ß 2002 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
Protein kinase Cj (PKCj) and S/V are the two known mem-
bers of atypical protein kinase C (aPKC) subfamily [1], and
have been implicated in cell proliferation and survival likely
through regulation of AP-1 and nuclear factor UB (NFUB)
activation pathways respectively [2^4]. In the NFUB activation
pathway, PKCj likely functions as an IUB kinase L (IKKL)
kinase [5]. Due to subtle structural di¡erences in the regula-
tory domain compared to those of classical and novel PKC
isoforms, aPKCs can not be activated by Ca2, diacylglycerol,
or phorbol esters [1], but seem to be regulated by other lipid
messengers such as ceramide [6] and phosphatidylinositol
3,4,5-P3 [7]. In addition, PKCj is also subjected to modula-
tion by protein regulators including prostate apoptosis re-
sponse-4 (PAR-4) and p62 [8,9].
The par-4 gene has been identi¢ed as an inducible gene in
neuronal and prostate cancer cells undergoing apoptosis [10].
Its implication in apoptotic cell death has been further sup-
ported by induced apoptosis of primary and immortalized cell
lines following ectopic expression of PAR-4 [11,12]. Several
lines of evidence suggest that the primary role of PAR-4 in
apoptotic process is to suppress the NFUB activation pathway
by binding to and inhibiting PKCj [8,13]. Usage of a zinc
¢nger in the regulatory domain of PKCj for its interaction
with PAR-4 [8] indicates that the interaction induces a con-
formational change and results in inhibition of the catalytic
activity of PKCj.
On the other hand, another PKCj binding protein p62 has
been suggested to play a critical role in PKCj-mediated NFUB
activation in a way that p62 recruits PKCj to the signaling
complex upon ligation of tumor necrosis factor-K (TNF-K),
interleukin-1, or nerve growth factor [15^17] without a¡ecting
its catalytic activity [14]. For instance, ligation of TNF recep-
tor activates the interaction of p62 with receptor interacting
protein (RIP), thus bringing PKCj to the TNF receptor sig-
naling complex where PKCj phosphorylates IKKL [5]. Inter-
estingly, the p62 gene can be induced by various extracellular
signals activating NFUB including treatment of cells with
PMA, serum, PDGF or oxidative stress [18,19].
All these results suggest the signi¢cance of the regulation of
PKCj in balancing the cell death and survival. As both PAR-
4 and p62 bind to PKCj and are products of inducible genes
under opposite states of the cell, dying and surviving respec-
tively, qualitative and quantitative control mechanisms for the
reciprocal regulation of PKCj by PAR-4 and p62 are to be
expected. In the present study, we have analyzed the regula-
tion of PKCj in regard to interactions with both PAR-4 and
p62.
2. Materials and methods
2.1. cDNA and constructs
cDNAs of PAR-4 and PKCj were cloned from HeLa cDNA library
(Clontech) by PCR. cDNAs were subcloned into pcDNA3.1-Myc/His
(Invitrogen) for mammalian cell expression, pEGFPN-1 (Clontech)
for green £uorescent protein-tagged expression, pGEX-4T1 (Pharma-
cia) for glutathione-S-transferase (GST) fusion protein expression and
pMALp2 (NEB) for maltose binding protein (MBP) fusion protein
expression. Truncation mutants of PAR-4 and p62 were generated by
PCR using appropriate primers, subcloned into proper expression
vectors and used.
2.2. Cell culture and immunoprecipitation
HeLa and U2OS cells were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
For immunoprecipitation, HeLa cells were lysed in the lysis bu¡er (50
mM HEPES (pH 7.5), 100 mM NaCl, 20 mM NaF, 1 mM DTT, 1%
Triton X-100, 5 mM EDTA, protease inhibitor cocktail (Calbiochem))
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on ice for 10 min. After removing insoluble materials by centrifuga-
tion at 4‡C, 2 Wg each of monoclonal antibodies against PAR-4 (Santa
Cruz) or p62 (Transduction Laboratory) was added to the lysate and
incubated for 2 h at 4‡C. Immune complex was then precipitated by
10 Wl of Protein G-agarose (Roche), washed three times with lysis
bu¡er, boiled in SDS sample bu¡er, and analyzed on the SDS^
PAGE followed by Western blot.
2.3. Transfection, NFUB reporter assay, FACS analysis, and
microscopic analysis
For NFUB reporter assay, cells in 24-well plates were transfected
with 0.4 Wg of DNA using lipofectamine-2000 (Gibco-BRL). Fresh
DMEM supplemented with 10% FBS was added at 3 h post-trans-
fection. 24 h later, transfectants were treated with TNF-K (20 ng/ml;
Calbiochem) for 6 h, and luciferase activity was determined using
dual-luciferase assay kit (Promega) according to manufacturer’s in-
structions. For microscopic analysis, cells were transfected with green
£uorescent protein-tagged PAR-4 (GFP-PAR-4) and p62 constructs
and observed under £uorescence microscope (OLYMPUS IX-70) at
48 h post-transfection. In order to examine the cell death rate, 105
transfected cells were harvested, washed twice with PBS, and sus-
pended in 100 Wl of Annexin V binding bu¡er (10 mM HEPES, pH
7.4, 140 mM NaCl, 2.5 mM CaCl2). 5 Wl of PE-Annexin V (BD
Pharmingen) was then added to the cell suspension and incubated
for 15 min at room temperature. After addition of 400 Wl of Annexin
V binding bu¡er, cells labeled with Annexin V were analyzed using
FACS Calibur (BD Bioscience) with CellQuest software.
2.4. In vitro translation and GST/MBP pull-down assay
In vitro translation was performed using an in vitro quick tran-
scription/translation kit (Promega) in the presence of 15 WCi of
[35S]methionine. cDNAs in pcDNA3.1 were used as template. Re-
combinant glutathione-S-transferase-fused PAR-4 (GST^PAR-4)
and MBP^p62 were expressed in Escherichia coli BL21(DE3) and
puri¢ed using Glutathione Sepharose-4B (Pharmacia) and amylose
resin (NEB), respectively, following manufacturer’s instructions. The
in vitro translated products in lysis bu¡er were pulled down by 1 Wg of
GST^PAR-4 or MBP^p62 bound to glutathione beads or amylose
beads, respectively. After a 2-h incubation, proteins bound to the
beads were washed three times with lysis bu¡er, boiled in 20 Wl of
SDS sample bu¡er, analyzed on the SDS^PAGE, followed by £uo-
rography.
2.5. In vitro kinase assay
Recombinant PKCj (Calbiochem) and puri¢ed GST^PAR-4 and
MBP^p62 were used for in vitro kinase assay. Myelin basic protein
(MyBP, Sigma), 10 WCi [Q-32P]ATP (30 Ci/mmol speci¢c activity,
Amersham PB10132) and phosphatidyl-serine (50 Wg/ml, sigma)
were used as substrates. The three recombinant proteins and sub-
strates were incubated in the kinase bu¡er (20 mM HEPES, pH 7.5,
10 mM L-glycerophosphate, 2 mM MgCl2, 2 mM MnCl2, 10 mM
PNPP, 1 mM DTT, 300 WM Na3VO4 and protease inhibitor cocktail)
for 30 min at room temperature. GST and MBP proteins were used as
controls to normalize protein concentration in the reaction mixture.
The reaction was stopped by adding 5U protein sample bu¡er and
analyzed on the SDS^PAGE and autoradiography.
3. Results
3.1. p62 antagonizes PAR-4-induced apoptotic cell death
Both PAR-4 and p62 are constitutively expressed in most
established cell lines thus far examined (Fig. 1A) despite the
fact that both proteins are the products of inducible genes
[10,18,19]. Furthermore, over-expression of GFP-PAR-4 but
not GFP alone induces apoptotic death of U2OS cells that
could be counteracted by co-expression of p62 (Fig. 1B).
These results suggest the presence of a balancing system for
cell death and survival controlled by PAR-4 and p62. This
could be through reciprocal regulation of their shared binding
target PKCj.
3.2. p62 and PAR-4 do not compete for PKCj but form
a ternary complex with PKCj
The counteractive role of p62 against the pro-apoptotic
activity of PAR-4 (Fig. 1B) could be a result of direct com-
petition for PKCj binding. Interestingly, however, both PAR-
4 and PKCj are found in the immune complex precipitated by
anti-p62 antibody (Fig. 2A). Reciprocally, both PKCj and
p62 are present in the complex brought down by using anti-
PAR-4 (Fig. 2B), and PAR-4 and p62 in the complex brought
down by using anti-PKCj (data not shown). This suggests a
ternary complex formation. Interestingly, recombinant GST^
PAR-4 but not GST alone pulls down the in vitro translated
Fig. 1. p62 antagonizes the e¡ect of PAR-4 in apoptotic cell death.
A: Expression of PAR-4, p62 and PKCj in various cell lines. Total
lysates of six cell lines were prepared (Section 2), and 50 Wg of ex-
tracts were separated on a 10% SDS^PAGE and analyzed by West-
ern blot using corresponding antibodies. B: U2OS cells were trans-
fected with pEGFP alone, pEGFP^PAR-4, or pEGFP-PAR-4 and
pcDNA1-p62 together. Cells were observed under £uorescence
microscope at 48 h post-transfection.
Fig. 2. Ternary complex formation of PKCj, PAR-4 and p62. A,B:
HeLa cell lysate was immunoprecipitated (IP) either with anti-p62
(A) or with anti-PAR-4 (B) antibody, and coprecipitated proteins
were analyzed by Western blot (WB) as described in Section 2. Pre-
cipitation with non-immune serum (NS) has been used to determine
the speci¢city of antibodies. C: In vitro translated PAR-4 and p62
were incubated in the lysis bu¡er with MBP^p62 and GST^PAR-4
respectively. After washing, bound proteins were separated on the
SDS^PAGE and visualized by £uorography. D: In vitro translated
PKCj was incubated with 1 Wg of GST^PAR-4 bound to gluta-
thione beads in the presence of increasing amounts of MBP^p62
(0.5, 1.0, 2.0 and 5.0 Wg) or MBP (1.0, 2.0 and 5.0 Wg). Bound
PKCj and p62 were separated on the SDS^PAGE and visualized
by £uorography for PKCj and Western blot analysis for MBP^p62.
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p62, while MBP^p62, but not MBP alone, precipitates the in
vitro translated PAR-4 (Fig. 2C). Furthermore, 1 Wg of GST^
PAR-4 e⁄ciently pulls down the in vitro translated p62 and
PKCj, but addition of increasing amount of MBP^p62 up to
5 Wg does not a¡ect the PAR-4^PKCj interaction (Fig. 2D).
Thus, p62 and PAR-4 do not compete for binding to PKCj.
Rather, p62 and PAR-4 form a ternary complex with PKCj
through direct interactions of all three components. In addi-
tion, mapping study shows that a short segment in the N-
terminal region (amino acids 50^80) of p62 and the leucine
zipper region in the C-terminus of PAR-4 are essential for
their interaction (Fig. 3). Thus, the C-terminal 183 amino
acids of p62 containing ubiquitin binding site [20] is dispens-
able for PKCj binding.
3.3. p62 and PAR-4 have opposite e¡ects on the
catalytic activity of PKCj
Next we analyzed the e¡ect of p62 binding on regulation of
the catalytic activity of PKCj (Fig. 4). Interestingly, recombi-
nant PKCj shows constitutive kinase activity for MyBP (Fig.
4A, lane 1). This was enhanced by p62 in some extent repro-
ducibly (Fig. 4A, lane 2). On the other hand, PAR-4 inhibited
this activity more than three folds, that is consistent with
previous reports (Fig. 4A, lane 3 and ref. [8]). Moreover,
the inhibited PKCj catalytic activity by PAR-4 was fully re-
stored, in a dose-dependent manner, by addition of p62 (Fig.
4A, lanes 4 and 5 and Fig. 4B). However, increasing amount
of PAR-4 did not inhibit the catalytic activity of PKCj, which
was pre-incubated with p62 (Fig. 4C). These results suggest
that p62 indeed modulates the inhibitory activity of PAR-4
for PKCj and restores the catalytic activity of PAR-4-bound
PKCj by forming a ternary complex.
3.4. p62 restores the PAR-4-mediated suppressed
NFUB activity and protects cells from apoptotic death
PKCj has been recognized as an IKKL kinase in the TNF-
K signaling pathway [5]. Thus, modulation of the catalytic
activity of PKCj would a¡ect TNF-K-induced NFUB activa-
tion and thereby the survival of the cell. Indeed, ectopic ex-
pression of PAR-4 suppresses TNF-K-induced NFUB activa-
tion by approximately four folds (Fig. 5A). Co-expression of
wild type or N-terminal 256 amino acids (p62N256) but not
C-terminal 183 amino acids (p62C183) of p62 restored the
NFUB activity (Fig. 5A). Furthermore, U2OS cells expressing
PAR-4 undergoes apoptosis, while cells cotransfected with
p62 or p62N256 but not p62C183 were relatively resistant
to PAR-4-induced apoptotic cell death (Fig. 5B). These results
Fig. 3. Leucine zipper domain in PAR-4 and a small region in N-
terminus of p62 is critical for interaction. A,C: Schematic diagrams
of truncation mutants of p62 (A) and PAR-4 (C) used in domain
mapping study. B,D: In vitro translated p62 (B) and PAR-4 (D)
proteins were pulled down using GST^PAR-4 and MBP^p62, re-
spectively. Inputs of the in vitro translated p62 and PAR-4 were ad-
justed to a similar level for each lane. After washing, bound pro-
teins were separated on the SDS^PAGE and visualized by
£uorography. Speci¢cally precipitated bands are marked with aster-
isks. p62 N, amino acids 1^256; p62 C, amino acids 257^439; p62
Nv50, amino acids 51^256; p62 N80, amino acids 1^80; PAR-4
vLZ, amino acids 1^303; PAR-4 C, amino acids 134^342; PAR-4
N, amino acids 1^133.
Fig. 4. p62 regulates the catalytic activity of free and PAR-4-bound PKCj. A: The catalytic activity of recombinant PKCj (200 ng) in the
presence of 200 ng each of PAR-4 and/or p62 was measured as described in Section 2. B,C: PKCj (200 ng) kinase reaction was performed in
the presence of 200 ng of GST^PAR-4 and increasing amounts of MBP^p62 (0, 50, 200 and 400 ng) (B) or in the presence of 200 ng of MBP^
p62 and increasing amounts of GST^PAR-4 (0, 50, 100, 200 and 400 ng) (C) for 30 min at room temperature as described in Section 2. Rela-
tive radioactivity was measured by densitometry using LAS-1000 (Fuji) and presented as relative kinase activity (the mean þ S.D. of three ex-
periments A: 16.3%, B: 6.0%, C: 4.6%) in bar graphs. Each autoradiogram is the representative of three independent experiments.
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are consistent with the facts that binding sites for both PKCj
and PAR-4 are localized in the N-terminal region of p62 (Fig.
3 and ref. [9]) and that p62N256 but not p62C183 reactivates
the catalytic activity of PAR-4-bound PKCj in a manner
similar to full length p62 (data not shown). Thus, binding
of the N-terminal region of p62 to the PKCj^PAR-4 complex
is su⁄cient to restore the PKCj catalytic activity and the
pathway for NFUB activation that prevents cells from apo-
ptotic death.
4. Discussion
PAR-4 and p62 are two known PKCj binding proteins
[8,9]. In the previous reports, it was suggested that p62 acts
as an adapter that facilitates NFUB activation by linking
PKCj to RIP or tumor necrosis factor receptor associated
factor-6 (TRAF-6) [16,17] without a¡ecting the catalytic ac-
tivity of PKCj [14]. Furthermore, it was shown that PAR-4
blocks NFUB activation by inhibiting PKCj activity [8]. Re-
sults presented in this study basically support the previous
¢ndings; PAR-4 inhibits PKCj (Fig. 4), suppresses TNF-K-
induced NFUB activation, and induces apoptotic cell death
(Fig. 5). However, our results suggest that p62 also plays
critical roles in the regulation of PKCj activity in addition
to the previously observed adapter function.
Interestingly, in four independent reconstitution experi-
ments using puri¢ed recombinant proteins, p62 binding con-
sistently enhanced the catalytic activity of PKCj up to 50%
(Fig. 4A). Furthermore, PAR-4 and p62 did not compete for
PKCj binding. Instead, they interacted directly with each
other and also simultaneously bound to PKCj (Fig. 2).
More interestingly, p62 restored the catalytic activity of
PAR-4-bound PKCj by forming a ternary complex (Figs. 2
and 4). Thus, direct regulation of PKCj and antagonistic
function in regard to PAR-4 would represent the roles of
p62, at least partly, in activation of NFUB.
However, this model still cannot explain the death of p62-
expressing cells caused by an increase of cellular PAR-4 level
(Figs. 1 and 5, and ref.[10]). The experiments showed that
PAR-4 did not compete with p62 for PKCj binding (Fig. 2)
and that p62-bound PKCj was active even in the ternary
complex with PAR-4 (Fig. 4B,C). Thus, if the adapter func-
tion of p62 is an absolute requirement for the PKCj-mediated
NFUB activation, the increased cellular level of PAR-4 would
not be expected to a¡ect the NFUB signaling pathway. How-
ever, increased PAR-4 level clearly blocked the NFUB activa-
tion and induced the apoptotic cell death (Fig. 5). It is thus
possible that, although p62 binds to both PKCj and RIP or
TRAF-6 [16,17], the adapter function may not be su⁄cient in
NFUB signaling. Rather, cellular population of catalytically
active PKCj, free and p62 occupied forms, may be important
in the signaling where the free PKCj will be the target of
PAR-4-mediated inhibition.
The expression of PAR-4 sensitizes most cell lines to apo-
ptosis by Ca2, low serum, or TNF-K [8,21,22]. It has also
been shown that ectopic expression of PAR-4 alone caused
apoptotic death of prostate cancer cells and tumors [23]. In-
terestingly, U2OS cells underwent spontaneous apoptotic
death by ectopic expression of PAR-4 alone without any
changes in culture condition (Figs. 1B and 5B). On the other
hand, the expression of PAR-4 alone induced apoptosis of
HeLa, HEK293, and SaOS2 cells only moderately (data not
shown). Particularly low p62 expression level in U2OS cells
(Fig. 1A) may have implication for this di¡erence. Sensitiza-
tion but not direct apoptosis of most cell lines by the PAR-4
expression could be, at least partly, due to the basal activity of
Erk which is another regulatory target of PKCj [24]. As only
p62-bound PKCj is catalytically active when PAR-4 is over-
expressed, U2OS cells would have limited PKCj activity that
may be insu⁄cient to maintain the basal Erk activity and to
keep the cells surviving. Nevertheless, further analysis of the
role of p62 will provide better understanding in PAR-4-medi-
ated apoptosis and sensitization of the cell.
The antagonism between p62 and PAR-4 in respect to
PKCj regulation could be explained by the topology of the
binding between the three proteins. The N-terminal amino
acids 50^80 and the leucine zipper region of p62 and PAR-
4, respectively, are essential for the interaction (Fig. 4). Ap-
Fig. 5. p62 reverses the PAR-4-mediated NFUB inhibition and cell death. A: E¡ects of wild type (WT), the N-terminal 256 amino acids
(p62N256, N) and the C-terminal 183 amino acids (p62C183, C) of p62 on the TNF-K-induced NFUB activation were compared. NFUB report-
er activity of U2OS cells transfected with cDNAs encoding PAR-4 and/or various p62 mutant proteins was measured after treatment of cells
with TNF-K (20 ng/ml) for 6 h as described in Section 2. Each data point is a mean of triplicated samples, and the ¢gure is the representative
of ¢ve independent experiments. B: U2OS cells transfected with cDNAs encoding vector alone or PAR-4 and various p62 proteins (wild type
(WT), p62N256 (N) or p62C183 (C)) were analyzed for their apoptotic death by measuring Annexin V-labeled cells following the procedures
described in Section 2. Percentage of Annexin V positive cells is marked in each histogram.
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parently weaker binding of p62Nv50 than that of p62N80 to
PAR-4 indicates that the further N-terminal region of p62 is
important for the e⁄cient binding to PAR-4. The amino acids
41^105 of the rat homolog of p62 and the leucine zipper
region of PAR-4 have been shown to be responsible for their
PKCj bindings [8,9]. Furthermore, the zinc ¢nger-like cysteine
rich region in the regulatory domain of PKCj is the binding
site for both p62 and PAR-4 [8,9]. The close proximity of
binding regions in each component of the ternary complex
strongly suggests that there will be distinct changes in confor-
mation of PKCj by binding of PAR-4, p62, or PAR-4 and
p62 together. Nevertheless, although there would be more
cellular targets of PAR-4 and p62, further analysis of PKCj
regulation in the context of the ternary complex will provide
better understandings in the signaling pathway for NFUB ac-
tivation and in the cell death and survival.
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